Publikácie
Údaje aktualizované: 20.10.2026 14:29 · Počet záznamov: 28 Zrušiť filtre
| Rok vydania / Kategória | Publikácia |
2025 V2 | Konflikty vo farmácii, príležitosti a výzvy Martin Višňanský, Štefania Laca Megyesi Dialóg o mediácii. Inšpirácia pre riešenie konfliktov |
2024 V3 | Leber hereditary optic neuropathy in Czechia and Slovakia: Quality of life and costs from patient perspective Beáta Bušányová, Marie Vajter, Silvie Kelifová, Petra Lišková, Hedviga Miková, Katarína Breciková, Ján Žigmond, Vladimír Rogalewicz, Aleš Tichopád, Martin Višňanský, Ivana Šarkanová HeliyonIF 3.4IF5 3.9SJR Q 1JCR Q 2SJR 0.627ABDC 0.613Rok scientometrie 2024 |
2024 V3 | Leber hereditary optic neuropathy in Slovenia: quality of life and costs from patient perspective Marko Hawlina, Lea Kovač, Katarína Breciková, Ján Žigmond, Vladimír Rogalewicz, Aleš Tichopád, Martin Višňanský, Ivana Šarkanová Orphanet journal of rare diseasesIF 3.5IF5 4SJR Q 1JCR Q 2SJR 1.269ABDC 1.28Rok scientometrie 2024 |
2024 V3 | The checklist for standard methodological requirements and reporting of economic evaluation of medicines in Slovakia Mária Bucek Pšenková, Lucia Hlavinková, Martin Višňanský, Dominik Grega, Martina Ondrušová Value in Health Regional IssuesIF 1.5IF5 1.7SJR Q 1JCR Q 3SJR 0.626ABDC 0.507Rok scientometrie 2024 |
2022 V3 | Average CET limit: Is it possible to introduce a single CET for the whole EEA? Dominik Grega, Jozef Kolář, Martin Višňanský Value In HealthIF 4.5IF5 6.2SJR Q 1JCR Q 1SJR 1.414H-index 124ABDC 2.094Rok scientometrie 2022 |
2020 BCI | Manažment pre študentov farmácie Jana Korimová, Martin Višňanský |
2020 BCI | Základy práva pre študentov farmácie Peter Korim, Monika Fedorová, Martin Višňanský rec. Jaroslav Legáth, Tomáš Wolaschka |
2019 AFD | Financovanie inovatívnych medicínskych technológií Martin Višňanský Škola - Veda - Prax, 17.-18. september 2019, Košice |
2018 ADF | Hodnotenie hodnotení - lieky (2016-2017) Martin Višňanský Farmakoekonomika a lieková politika |
2018 AFG | Impact of the international reference pricing on access to standard therapy drugs for copd Martin Višňanský, Anna Butalová Value In HealthIF 5.037IF5 6.131SJR Q 1JCR Q 1SJR 1.836H-index 97ABDC 2.082Rok scientometrie 2018 |
2018 AFG | Is transparency in slovak hta efficient enought? Comparing pharmacoeconomics methodologies used in pricing & reimbursement applications for innovative therapies towards requirements defined by the law Martin Višňanský Value In HealthIF 5.037IF5 6.131SJR Q 1JCR Q 1SJR 1.836H-index 97ABDC 2.082Rok scientometrie 2018 |
2017 ADF | Hodnotenie zdravotníckych technológií a hodnota za peniaze v liekovej politike Martin Višňanský, Radoslav Suchovič Onkológia |
2017 ADF | Inovácie vo farmaceutickom priemysle EÚ - dopad na rozpočet SR Martin Višňanský Farmakoekonomika a lieková politika |
2017 ADM | The Drug Policy in Central European Countries - Slovakia Mária Bucek Pšenková, Martin Višňanský, Stanislava Mackovičová, Dominik Tomek Value in Health Regional IssuesSJR Q 2SJR 0.366H-index 15Rok scientometrie 2017 |
2016 ADF | HTA a personalizovaná medicína Martin Višňanský Farmakoekonomika a lieková politika |
2016 AFG | Impact of the international reference pricing on access to standard therapy drugs for asthma and COPD Martin Višňanský, Diana Kababiková Value In HealthIF 3.824IF5 4.491SJR Q 1JCR Q 1SJR 1.908H-index 97ABDC 1.63Rok scientometrie 2016 |
2016 AFG | International Reference pricing across EU Martin Višňanský Value In HealthIF 3.824IF5 4.491SJR Q 1JCR Q 1SJR 1.908H-index 97ABDC 1.63Rok scientometrie 2016 |
2015 AFG | A Novel Method for Calculating Medication Adherence to Poly-Pharmacotherapy by Linking General Practice Prescribing Data and Pharmacy Dispensing Records Tamás Ágh, András Inotai, László Szilberhorn, Josip Culig, Martin Višňanský, Zoltán Kaló, Guenka Petrova Value In HealthIF 3.824IF5 3.761SJR Q 1JCR Q 1SJR 1.736H-index 97ABDC 1.352Rok scientometrie 2015 |
2015 ADF | Vývoj hodnotenia zdravotníckych technológií v Európe Martin Višňanský Farmakoekonomika a lieková politika |
2013 BAA | Clinical Guidelines for Chronic Conditions in the European Union Helena Legido-Quigley, Dimitra Panteli, Josip Car, Martin McKee, Reinhard Busse |